These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9760148)

  • 41. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion.
    Carella AM; Podestà M; Frassoni F; Pungolino E; Pollicardo N; Raffo MR; Ferrero R; Benvenuto F; Figari O; Giordano D
    Stem Cells; 1993 Oct; 11 Suppl 3():67-72. PubMed ID: 7905325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
    Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML.
    Waller CF; Heinzinger M; Rosenstiel A; Lange W
    Br J Haematol; 1998 Oct; 103(1):227-34. PubMed ID: 9792314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mini-ice protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia.
    Carella AM
    Leuk Lymphoma; 2001 Jan; 40(3-4):447-8. PubMed ID: 11426572
    [No Abstract]   [Full Text] [Related]  

  • 46. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
    McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM
    Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
    Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
    J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
    Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy.
    Bose S; Chowdhry VP; Saxena R; Kucheria K
    Acta Haematol; 1997; 98(3):155-9. PubMed ID: 9352747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
    O'Brien S; Witt R; Talpaz M; Kantarjian H
    Cancer; 1991 Apr; 67(7):1946-9. PubMed ID: 2004308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
    Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
    Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
    Deininger M; Pönisch W; Krahl R; Leiblein S; Edel E; Lange T; Fiedler F; Freund M; Franke A; Pasold R; von Grünhagen U; Herold M; Dölken G; Hoffmann FA; Uhle R; Schultze W; Steglich J; Schwarzer A; Richter P; Winkelmann C; Kettner E; Dachselt K; Subert R; Schwalbe E; Doepper J; Helbig W; Niederwieser D;
    Bone Marrow Transplant; 2001 Jun; 27(11):1125-32. PubMed ID: 11551022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Autologous transplantation of Ph-negative peripheral blood stem cells for treatment of chronic myelogenous leukemia].
    Hatsuse M; Okano A; Okamoto A; Shimura K; Takahashi R; Hirai H; Ashihara E; Inaba T; Fujita N; Shimazaki C; Nakagawa M
    Rinsho Ketsueki; 2000 Aug; 41(8):671-5. PubMed ID: 11020996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha.
    Michallet M; Thiébaut A; Philip I; Charrin C; Vigouroux C; Thomas X; Bilger K; Belhabri A; Guyotat D; Corront B; Salles B; Dumontet C; Péaud PY; Vilque JP; Devidas A; Fière D
    Leukemia; 2000 Dec; 14(12):2064-9. PubMed ID: 11187894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
    Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
    Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete cytogenetic but not molecular remission in a patient with myeloid blast crisis of chronic myeloid leukemia treated with carboplatin and ara-C.
    Pérez-Simón JA; Caballero MD; Hernandez-Rivas JM; Chillón C; García-Isidoro M; San Miguel JF
    Haematologica; 1997; 82(5):604-5. PubMed ID: 9407733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.